Orforglipron linked to lower blood pressure across groups
Analyses of two randomized trials found broadly consistent reductions in the top blood pressure number among adults with obesity or overweight at 72 weeks.
Our read
Interventions- Studied:
- Randomized trial in people (72 weeks, placebo-controlled)
- In the record:
- The 33rd paper on orforglipron with results in people; 80 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with obesity or overweight, with or without type 2 diabetes, received orforglipron or placebo in two randomized trials. These post hoc analyses—additional analyses of the trial data—pooled the drug doses and examined blood pressure at 72 weeks.
Reductions in systolic blood pressure, the top number in a blood pressure reading, were broadly consistent across groups defined by starting characteristics. An exploratory analysis suggested that weight loss accounted for an estimated 58.3% of this reduction in ATTAIN-1, which excluded type 2 diabetes, and 80.8% in ATTAIN-2, which included it. Low-blood-pressure-related adverse events were uncommon but more frequent with orforglipron than placebo. Most were mild to moderate.
Why it matters
Blood-pressure management is relevant to healthy aging. Understanding its relationship with weight loss may help clarify what obesity therapies change beyond body weight.
Caveats
The post hoc analyses left possible blood-pressure effects independent of weight loss unresolved. The findings concern adults with obesity or overweight and do not establish effects in people outside those weight categories.
Where the evidence stands
Orforglipron
- 21 independent labs in 9 countries
- 1 finding against
- 36 trials, 1 with no results posted
- Funder: Eli Lilly and Company
- 35 of 82 findings with company ties
- 35 of 36 trials sponsored by its developers
The paper
Eli Lilly and Company Indianapolis Indiana USA
Diabetes, Obesity & Metabolism, Nov 10, 2026
Comments
Be the first to comment.